GC Biopharma USA, Inc., a leader in plasma-derived products, announced the presentation of new data on the viscosity of several commercially available 10% intravenous immunoglobulin (IVIG) products at ...

A rare Guillain-Barré syndrome recurrence caused nausea with no motor symptoms but was treated successfully with intravenous ...

GC Biopharma (006280.KS), a South Korean pharmaceutical company, announced that its varicella vaccine BARYCELA has received ...

Panelists discuss how preparing multiple myeloma patients for treatment involves structured education, emotional support, and proactive symptom management—emphasizing clear communication about the ...

During a live event, Jorge Monge, MD, discussed short and long-term adverse events associated with CAR T-cell therapy in ...

Annexon offers speculative upside with Tanruprubart, targeting Guillain-Barré Syndrome's unmet needs. Click here to read my ...

During a live event, Jeffrey V. Matous, MD, discussed bispecific antibody treatment efficacy and safety in advanced multiple ...

The European Commission (EC) has approved BeOne Medicines’ Tevimbra (tislelizumab) as part of a first-line combination ...

WHO has released its first-ever clinical guidelines to standardise treatment of mosquito-borne diseases like dengue, ...

AnaptysBio’s lead drug rosnilimab showed promise in RA, but lack of a Phase 3 plan and limited pipeline raise concerns. Find ...

The announced merger with THPlasma follows Longevity's acquisition of Carmell Therapeutics (“Carmell”) in July 2023 and Elevai Skincare (“Elevai”) in January 2025. The Carmell technology platform is ...

WHO has released its first unified clinical guidelines for managing dengue, Zika, chikungunya, and yellow fever, aiming to ...